Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96: 2943-2950.{line break}Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.{line break}Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic Applications. Oncogene 2001, 20: 4519-4527.{line break}Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001,20: 5991-6000.{line break}Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dong L, Castro A, Palombella V, Adams J, Anderson KC. NF-kappaB as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647.{line break}Hideshima T and Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2:927-937.{line break}Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003, 101:703-705.{line break}Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Poda K, Munshi NC, Mitsiades N, Anderson KC. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 2003, 101:1530-1534.{line break}Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson PG, Anderson KC. Biologic Sequelae of c-Jun NH2-Terminal Kinase (JNK) Activation in Multiple Myeloma Cell Lines. Oncogene 2003, 22:8797-8801{line break}Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogen 2003, 22:8386-839l.{line break}Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, Mitsiades N, Gong B, Bonham L, de Vries L, Richardson PG, Singer JW, Anderson KC. Anti-Tumor Activity of Lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res 2003, 63:8428-8436.{line break}Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai Y-T, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004, 23:8766-8776.{line break}Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104:607-618.{line break}Hideshima T, Chauhan D, Ishitsuka K, Yasui H, Raje N, Kumar S, Podar K, Mitsiades C, Hideshima H, Bonham L, Munshi NC, Richardson PG, Singer JW, Anderson KC. Molecular characterization of PS-341 (bortezomib) resistance: Implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene, 2005, 24:3121-3129.{line break}Hideshima T, Bradner J, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005, 102: 8567-8572.{line break}Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053-4062.{line break}Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC. MLN120B, a novel IKKbeta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res, 2006,12:5887-5894.{line break}Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis and the role of bone marrow microenvironment to identify new therapeutic targets. Nat Rev Cancer 2007, 8:585-98.{line break}Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Biologic Sequelae of IkappaB Kinase (IKK) Inhibition in Multiple Myeloma: Therapeutic Implications. Blood, 2009, 113:5228-5236{line break}Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Bortezomib induces canonical NF-kappaB activation in multiple myeloma cells. Blood, 2009, 114:1046-1052.{line break}